

# European Clinical Research Alliance on Infectious Diseases: ECRAID - Base

**FAIR-by-design, interoperability and CDISC**

Experiences, challenges, lessons learnt and future directions

Ankur Krishnan

21st November 2025





# Meet the Speaker

## Ankur Krishnan


**Title:** Data Steward and Project Manager

**Organization:** Heidelberg Institute of Global Health

Ankur is the Data and Project Manager at Heidelberg Institute of Global Health (HIGH) for the ECRAID-Base project. He led the design and implementation of the ECRAID-Base FAIR-by-design strategy, which includes: i) CDISC-compliant eCRFs for observational studies within ECRAID-Base, ii) cross-walks between CDISC – OMOP CDM (through EHDEN project) and CDISC – HL7 FHIR (through Horizon Standardization Booster project), iii) machine-actionable study- and site-level metadata schemas and, iv) machine-actionable Data Management Plan (DMP).


Ankur has over 7 years of experience in data standards, harmonization, collection and management within the translational and evidence-based clinical research landscape. And, 9 years of experience in project management.

He holds Master's degrees in Forensic Science (2011 – 2013: NICFS, New Delhi, India) and Applied Biotechnology (2016 – 2018: McGill University, Montreal, Canada).




# Disclaimer and Disclosures

- *The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of CDISC.*
- *The ECRAID-Base project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 965313*
- *The author(s) have no real or apparent conflicts of interest to report.*



# Agenda

1. Introduction
2. ECRAID-Base and FAIR-by-design
3. CDISC-compliant CRF development: 'central library' approach
4. Experiences and lessons
5. Considerations and Recommendations



# Introduction

Ecraid network, ECRAID-Base and Perpetual Observational Studies

# ECRAID-Base

European Union's **Horizon 2020** funded project

Establishes a 'warm-base' pan-European clinical research network

Facilitates faster, easier and cost-effective **infectious diseases (ID) and antimicrobial resistance (AMR) research** to reduce their impact on individual and population health in Europe.

## Pandemic preparedness and response

The network has the capacity and capability to:

- directly enrol patients with infectious diseases
- conduct a broad range of rigorous clinical studies efficiently and rapidly
- function as a platform for a rapid research response in the face of serious infectious disease outbreaks

## ecraid Network

### CLIN-Net

**Network of clinics and hospitals** capable of quickly and reliably recruiting, treating, monitoring and reporting data for multinational, multicenter studies

### LAB-Net

**Network of microbiology experts and laboratories** delivering high-quality and standardized information on microbial strains and antibiotic resistance

### STAT-Net

**Network of statistics and clinical study design experts** in infectious diseases (ID) and antimicrobial resistance (AMR) research

### EPI-Net

**Network of ID/AMR epidemiology and surveillance experts**

### Penta ID

**Network devoted to advancing research on optimising the prevention, diagnosis and treatment of infectious diseases in children and in pregnancy**

# • ECRAID-Base Consortium

19 organisations based in ten countries: Belgium, Croatia, Czech Republic, Italy, Germany, France, the Netherlands, Spain, Switzerland, and the United Kingdom.



UMC Utrecht



Universiteit  
Antwerpen



icnarc



UNIVERSITY OF  
OXFORD



Centre hospitalier universitaire  
Limoges



UNIVERSITÀ  
di VERONA



UNIVERSITÄTS  
KLINIKUM  
HEIDELBERG



EUROPEAN  
SOCIETY  
OF CLINICAL  
MICROBIOLOGY  
AND INFECTIOUS  
DISEASES



#ClearDataClearImpact

# Perpetual Observational Studies (POS)

The first studies to benefit from Ecraid's infrastructure are -

- **Five Perpetual Observational Studies (POS)**
- European arm of the REMAP-CAP adaptive platform trial

A POS is a **prospective, multicentre, observational clinical study** that perpetually enrolls patients

They address key clinical research gaps, including variations in clinical practices, incidence and prevalence of IDs, AMR and associated risk factors.

Clinical research backbone, **ready to concurrently or sequentially embed studies** (observational, experimental, investigator-initiated, or commercial)

**Data types:** Demographic, Comorbidities, Disease-specific, Sample provenance, Diagnostic testing, Microbiology and AST, Outcomes

Additionally, **site-, laboratory- and study-level metadata**

**Data sources:** eCRFs, LIMS, site surveys, laboratory questionnaires

## Ventilator-Associated Pneumonia in ICUs

### POS-VAP

Started - August 2022  
6761 participants enrolled  
Across 40 sites

## Complicated Urinary Tract Infections in Hospitals

### POS-cUTI

Started - October 2022  
5777 participants enrolled  
Across 43 sites

## Acute Respiratory Infections in Emergency Rooms

### POS-ARI-ER

Started - June 2023  
3710 participants enrolled  
Across 42 sites

## Acute Respiratory Infections in Primary Care

### POS-ARI-PC

Started - February 2024  
1209 participants enrolled  
Across 11 sites

## Unexplained febrile illness with unusual epidemiology and/or clinical presentation in Emergency Rooms


### POS-Disease X

Started - December 2023  
38 participants enrolled  
Across 8 sites

## Community-Acquired Pneumonia in Hospitals

### REMAP-CAP (Europe)

Started - March 2018  
8554 participants enrolled  
Across 131 sites




# ECRAID-Base and FAIR-by-design

## Open Science and FAIR principles

# Open Science and FAIR principles



Findable Accessible Interoperable Reusable



Findable Accessible Interoperable Reusable

## Benefits of Open Science

 Researchers	 Funders	 General Public
<ul style="list-style-type: none"><li>• greater visibility &amp; reach</li><li>• increased efficiency</li><li>• funding</li><li>• collaboration/networking</li></ul>	<ul style="list-style-type: none"><li>• increased visibility &amp; reuse of funded research</li><li>• greater funding impact</li><li>• greater ROI</li></ul>	<ul style="list-style-type: none"><li>• faster knowledge transfer</li><li>• increased understanding and expertise</li><li>• promoting engagement in science &amp; research</li></ul>
 Organisations/NGOs	 National Governments	
<ul style="list-style-type: none"><li>• enhanced access to research</li><li>• more effective advocacy/lobbying</li></ul>	<ul style="list-style-type: none"><li>• evidence-informed policy</li><li>• promoting Human Rights and democracy</li></ul>	

ECRAID-Base operates under the maxims:

- As open as possible and as closed as necessary
- FAIR-by-design

# Planning and decision-making

Proactive

Prospective

Purpose-driven

Representing different stakeholders, expertise and perspectives

Harmonization v/s Standardization

Extent of prospective standardization possible

Within project

Beyond project

FAIR and Open Science

Risks and benefits

Existing tools and resources

**Research plans and scientific objectives**

**Awareness and discourse**

**Ethics and Governance**

External i.e. services and initiatives

Internal i.e. at a project and/or institution level

Allocation of resources


**Capacity**

**Funding and Budgeting**

**Sustainability**

**FAIR-by-design**

# Planning and decision-making



Global Alliance  
for Genomics & Health  
Collaborate. Innovate. Accelerate.




Broad consent  
for future use




# How CDISC helps ECRAID-Base deliver on its mission

<b>Compliance</b>	<ul style="list-style-type: none"><li>● Submission ready core dataset that can be expanded for intervention studies that respond to (re)emerging IDs</li><li>● Historical controls, external control arms to facilitate RCT</li><li>● RWD to better the definition of clinical endpoints in trials</li></ul>
<b>Interoperability</b>	<ul style="list-style-type: none"><li>● Between POs</li><li>● Across related ID studies, including antimicrobial resistance (AMR)</li></ul>
<b>Utility</b>	<ul style="list-style-type: none"><li>● Real-time AMR surveillance by EPI-Net</li><li>● FAIR-by-design data to enhance reuse</li><li>● CDISC-compliant, prospectively-harmonized eCRFs</li></ul>



## CDISC-compliant, FAIR-by-design CRF development: A 'central library' approach



# ‘Central library’ approach - CRF development

Developed list of domains/CRFs based on the existing CDISC domains (e.g., Demographics, Vital Signs, etc.) and commonly used CRFs in observational studies on ID

Study teams indicated the domains/CRFs relevant for their study to establish a set of ‘common domains/CRFs’ across studies.

Any domain/CRF indicated by more than one study team was included in the ‘central library’

The common domains/CRFs were populated with variables and controlled terminology using -

- CDISC resources (IGs, eCRF portal, TAUGs, etc.)
- ISARIC COVID-19 CRFs
- CRFs of existing studies on the disease area (led by the study teams)
- Input from study teams, LAB-Net and EPI-Net.

# Alignment between common domains/CRFs in 'central library' and CDISC domains

Common form	CDISC domain
Informed consent	DS domain
Screening - Inclusion/Exclusion criteria	DS domain
Admission details	HO domain
Demographics	DM, SC and RP domain
Vital signs	VS domain
Predictive scores and scales	QRS domain
Comorbidities and Risk factors	MH domain
Prior and Concomitant Medications (including vaccination history)	CM domain
Signs and symptoms	CE domain

Common form	CDISC domain
Laboratory tests	LB domain
Radiological tests	PR and FA domains
Microbiological Identification and Susceptibility testing	MB and MS domains
Treatment	CM and PR domains
Events and complications	CE, AE and FA domains
Microbiological cure	MB and MS domains
Outcomes	DS, DD, HO and FA domains
Withdrawal	DS domain
Exposures and Recent Travel	ER domain

# 'Central library' approach - CRF development

## Master lists and Controlled Terminologies

Created master lists of controlled terminologies with study teams, for -


- Diseases and health conditions (MedDRA/ICD-10)
- Specimen types
- List of Pathogens provided by LAB-Net (mapped to CDISC CT/NCBI taxonomic IDs)
- Resistance Mechanisms/Profiles
- Antimicrobial agents (ATC)

## POS-specific eCRF development

- Study team chose the data items and categories/controlled terminologies in each common form and master list, that need to be collected for their study
- Any new study specific data items and forms were mapped to CDASH/SDTM
- Where a variable could not be mapped to CDASH/SDTM, we created Non Standard Variables (NSV)/supplemental qualifier.

POS name	% of variables mapped to CDASH/SDTM	% of NSVs	% of variables for internal data management *
POS-ICU-VAP	81	15	4
POS-cUTI	85	12	3
POS-ER-ARI	88	7	5
POS-PC-ARI	68	30	2
POS-ER-Disease X	83	14	3

- Based on the total number of variables, variables mapped to CDASH and NSVs created, for each study
- POS-PC-ARI highly preferred to use CRFs from their previous point-prevalence audit survey studies. Did not use 'central library' approach. Study CRFs aligned to 'central library' and mapped to CDASH/SDTM, as best possible
- **POS-ER-Disease X will export laboratory and microbiological data directly from the sites** (i.e., not captured via eCRF). Align and map each sites data export format to 'central library' and CDASH/SDTM



## Experiences and lessons

# CDISC resources & support

We used CDASH and SDTM IGs, CDISC library, CDISC wiki, CDISC Knowledge base, CDISC eCRF portal, CDISC TAUGs and existing studies/use cases such as ISARIC COVID-19 CRFs

- **Internal support** (at the beginning) - Steve Canham, ECRIN
- **External support** (towards the end) - Gary Walker, CDISC
- Subsequent to our mapping work, we found the **CDISC RWD webinar** and **JMIR Medical Informatics article** helpful and encouraging

Challenges -

- At the beginning, identifying and **understanding how to navigate and use the resources was difficult**
- **Implementation guides are ~ 450-page documents**
- **CDISC library and wiki are great for targeted searches** i.e., one has some prior (at least basic) understanding of the standards
- **Access to CDISC implementation support/expert**
  - Cost-prohibitive to have CDISC support/expert on retainer in government-funded research projects

# Understanding CDASH and SDTM for CRF design and development

## Important considerations during CRF development -

- Study-, disease area- and setting-specific data collection needs and practices
- Minimizing the burden of data collection
- Aligning with end-users needs and objectives such as EPI-Net, STAT-Net
- CDASH/SDTM IGs and conformance rules

## Finding the balance between -

Pushing the study team to change the format of their variable to fit CDASH/SDTM IG and rules

- Bending conformance rule(s)
- Creating a new Non-standard variable (NSV)/supplemental qualifier


At times, **understanding SDTM was important when designing CRFs** because how data are tabulated in SDTM affects –

- Descriptive metadata collection (e.g., anatomical location where temperature was taken)
- How variables should be partitioned (or not)

## Specimen types such as Endotracheal aspirate, Bronchoalveolar Lavage and Suprapubic Aspirate

- **From a CDASH/SDTM perspective**, better to collect them as Specimen material type, Anatomical location and Method variables, separately, in the CRF
- **From a clinicians/researcher's perspective**, these are commonly collected specimens. Splitting them in CRF would not make sense and likely, increase the burden of data collection
- Best approach to request them as new terms in CDISC CT?

Sample type	MBSPEC (SPECTYPE Codelist)	MBLOC (LOC Codelist)	MBMETHOD (METHOD Codelist)
Endotracheal aspirate/fluid	Endotracheal Aspirate/Fluid	Trachea	Not found
Bronchoalveolar lavage	Lavage Fluid	Lower Respiratory System OR MBLOC = Multiple; MBLOC1 = Bronchus; MBLOC2 = Alveolus	Not found
Suprapubic Aspirate	??	Suprapubic Region	Not found



# CDISC Controlled Terminology and other external terminologies

## Potential variations across geographical areas, cultures and laboratory practices


- **RACE and ETHNIC codelists**
  - Not extensible
  - Controlled terminologies in codelists are US-centric
  - CDISC CT could not be used for our EU-based studies
- **MBTEST, MSTEST and METHOD codelists**
  - Extensible
  - Some of the tests and methods used by laboratories in our network were not available in the codelists or could not be mapped completely (loss of granularity)

## Difficult to know **when to extend CDISC CT codelist versus when to bring in a different, external terminology**

- Effect of this on compliance

## Potential effect on semantic interoperability and regulatory compliance of -


- Extending CDISC CT (codelist)
- Using external CTs
- Sponsor-defined codelists
- Non-standard variables



# CDASH/SDTM mapping - an observational study design perspective

## Signs and Symptoms, Onset date, Diagnosis, Recurrence and Reinfection in CDISC -

- In our studies -
  - **At Day 0/VAP screening** - Signs and Symptoms, Date of Onset and (Working) Diagnosis
  - **At Day 14** - Follow-up assessment of Signs and Symptoms, Primary Diagnosis
  - **At Day 30** - Reinfection and Recurrence
- As per CDASHIG and TAUGs, multiple approaches possible -
  - **CE and FA(CE) domain/dataset**
  - MH and FA(MH) domain/dataset; using MHEVDTYP
  - MH, SM (MIDS = "DIAGNOSIS") and FA(MH) domains/dataset
- How do we map Signs and Symptoms, Date of Onset, Date of Diagnosis (Working and Final), Date of Reinfection and Recurrence within the CE domain?
- --EVDTYP (using EVDTYP codelist) for CE domain or something similar might be needed



# How do we measure & validate CDISC conformance?

Our study data will be **converted to SDTM, only when needed**.

We were lucky to have **Gary Walker (Implementation expert, CDISC)** to help us review new variables for conformance

How do we measure CDISC conformance during CRF development?

*Jentoft et al., Journal of the Society for Clinical Data Management 2(3), 2023*


- Ongoing SDTM conversion throughout the trial
- Provided SAS data exports every two weeks to an external CDISC consultant, to create and update the SDTMs
- Consultant exported the SDTM output to the Pinnacle 21 data review validator
- Data or structural issues resolved

Not ideal (maybe, not even possible from a time and resources perspective) in our project


# How do we maintain CDISC conformance & interoperability?

Sample type	During CRF development - SDTMIG v3.3 (SDTM v1.7)			SDTMIG v3.4 (SDTM v2.0)		
	MBSPEC (SPECTYPE Codelist)	MBLOC (LOC Codelist)	MBMETHOD (METHOD Codelist)	BSSPEC (SPECTYPE Codelist)	BELOC (LOC Codelist)	BECLMETH (CLMETH Codelist)
Endotracheal aspirate/fluid	Endotracheal Fluid	Trachea	Not found	Endotracheal Fluid	Trachea	Aspiration
Bronchoalveolar lavage	Lavage Fluid	Lower Respiratory System OR MBLOC = Multiple; MBLOC1 = Bronchus; MBLOC2 = Alveolus	Not found	Lavage Fluid	Lower Respiratory System OR MBLOC = Multiple; MBLOC1 = Bronchus; MBLOC2 = Alveolus	Lavage
Suprapubic Aspiration	??	Suprapubic Region	Not found	??	Suprapubic Region	Aspiration

How are these differences reconciled across versions of CDISC? How do you know the level of interoperability between CDISC versions?




# Considerations and Recommendations




# General challenges

- Deciding on an ontology
- Making judicious use of standards' flexibility
- Determining a budget for applying CDISC or any ontology
- Convincing the PI/funder that the budget for applying CDISC of any ontology is warranted
- Building & keeping talent
- Linking stakeholders (Researchers, Funding bodies, Regulatory bodies, and Standard Developing Organizations) to share responsibility and take action on multiple levels (e.g., funding mandates, training, improved tooling for standards implementation)
- Need for crosswalks between CDISC, OMOP-CDM and HL7-FHIR and other standards (fractured FAIR landscape)



# Considerations

- CDISC, through CDASH, enables FAIR-by-design CRF development approaches
- CDISC data standards are very well suited for the intersection of observational research/RWD and interventional research
  - Enables regulatory body submission compliance and FAIR principles
  - Highly important in Infectious Diseases and Antimicrobial Resistance research landscape
  - Can enable better outbreak preparedness and response
- CDISC has a different stakeholder landscape than some other commonly used standards and the focus on fit-for-regulatory submission may be more important than fit-for-cross-study interoperability
- CDISC is perhaps too rigid at times (observational study data might not be as conformant) and too flexible at others (study data might not be as interoperable)




# Recommendations for CDISC

- **Improved tooling and simplified guidance** to help orient new-users and to understand and navigate of existing CDISC resources
- **Cross-walks and standardization across standards and terminologies** used in healthcare research, to enable, encourage and enhance structural and semantic interoperability
- Some **mechanism to assess conformance** (perhaps, NLP-based) – ideally as CRF is being developed.
- Some **guidance/checks/SOPs** that can be incorporated into study's data validation plans and quality checks to ensure a level of conformance
- Guidance on **how compatible different versions of CDISC standards are with one another** to understand when to move to the next version
  - Some level of **automation for (re)mapping terms to new domains** when a new, more appropriate domain is established in a new version of CDISC

# Recommendations for CDISC

- **CDISC Portal -**
  - Researchers implementing CDISC can register
  - Provide details such as data source(s), research area, etc.
  - Submit keywords and highlight domains to tell CDISC what they are working on
  - Produces targeted updates if there are new domains added, updates to relevant domains, etc.
  - Researchers can notify of sponsor-defined categories, sub-categories and codelists
- **CDISC trained and certified SMEs**
  - Academic research projects can sub-contract (internal or external funding initiatives)
  - Support protocol and CRF development, conformance checks, etc.




# Acknowledgment

## ECRAID-Base

- Steven Canham
- Lauren Maxwell
- Frank Leus
- Lisanne Vincent
- Ellen van Deuren
- Roxanne Schaaks
- Thomas Jaenisch

## CDISC

- Gary Walker
- John Owen
- David Evans

A vertical decorative graphic on the left side of the slide. It consists of a grid of colored dots (red, yellow, green, blue) connected by dashed lines, forming a complex, branching pattern that resembles a network or a stylized tree.

# Thank You!

